F-Fluoroestradiol PET/CT for Staging Low-Grade Estrogen Receptor-Positive Breast Cancer.
作者信息
Fowler Amy M
机构信息
Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, Madison, WI 53792-3252.
University of Wisconsin Carbone Cancer Center, Madison, Wis.
出版信息
Radiology. 2025 Mar;314(3):e250135. doi: 10.1148/radiol.250135.
Abstract
摘要
相似文献
1
F-Fluoroestradiol PET/CT for Staging Low-Grade Estrogen Receptor-Positive Breast Cancer.F-氟雌二醇PET/CT用于低度雌激素受体阳性乳腺癌的分期
Radiology. 2025 Mar;314(3):e250135. doi: 10.1148/radiol.250135.
2
Utility of F-fluoroestradiol over F-fluorodeoxyglucose positron emission tomography/computed tomography in the initial diagnosis of over 90 metastatic lesions in a patient with metastatic estrogen receptor-positive breast cancer.在一名转移性雌激素受体阳性乳腺癌患者超过90处转移病灶的初始诊断中，F-氟雌二醇相较于F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的效用。
Proc (Bayl Univ Med Cent). 2024 Jul 29;37(6):984-986. doi: 10.1080/08998280.2024.2376972. eCollection 2024.
3
F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.F-氟雌二醇PET/CT预测雌激素受体阳性乳腺癌患者内分泌治疗获益的系统评价和Meta分析
J Nucl Med. 2025 May 1;66(5):692-699. doi: 10.2967/jnumed.124.269163.
4
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.患者间和患者内（部位间）的雌激素受体结合的变异性，通过 18F-氟雌二醇 PET 进行体内测量。
J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.
5
Can F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor-positive Breast Cancer Patient: A Prospective Comparative Study with F-Fluorodeoxyglucose Positron Emission Tomography?氟-雌二醇正电子发射断层扫描能否成为雌激素受体阳性乳腺癌患者的新成像标准：与氟-脱氧葡萄糖正电子发射断层扫描的前瞻性对比研究？
World J Nucl Med. 2017 Apr-Jun;16(2):133-139. doi: 10.4103/1450-1147.203071.
6
Comparison of diagnostic sensitivity of [F]fluoroestradiol and [F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer.[F]氟雌二醇与[F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对雌激素受体阳性原发性乳腺癌病史患者乳腺癌复发的诊断敏感性比较。
EJNMMI Res. 2020 May 24;10(1):54. doi: 10.1186/s13550-020-00643-z.
7
18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer.18F-氟雌二醇 PET/CT 正确诊断了一名雌激素受体阳性乳腺癌患者的 18F-FDG 摄取炎性淋巴结。
Clin Nucl Med. 2018 May;43(5):379-380. doi: 10.1097/RLU.0000000000002041.
8
F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.氟维司群 PET 显像在唑来膦酸治疗 ER+/HER2-转移性乳腺癌以恢复内分泌敏感性的 II 期试验中。
J Nucl Med. 2021 Feb;62(2):184-190. doi: 10.2967/jnumed.120.244459. Epub 2020 Jun 26.
9
Diagnostic Potential of Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.镓标记新硼酸盐正电子发射断层显像/计算机断层扫描（Ga-NeoB PET/CT）对雌激素受体和孕激素受体阳性乳腺癌进行转移灶分期或再分期的诊断潜力
J Nucl Med. 2025 May 1;66(5):700-706. doi: 10.2967/jnumed.124.268896.
10
The Predictive Value of Early Changes in F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.氟[18F]雌二醇正电子发射断层扫描/计算机断层扫描在氟维司群 500mg 治疗雌激素受体阳性转移性乳腺癌患者中早期变化的预测价值。
Oncologist. 2020 Nov;25(11):927-936. doi: 10.1634/theoncologist.2019-0561. Epub 2020 Apr 28.
本文引用的文献
1
The Diagnostic Accuracy of F-FDG PET and F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer.F-FDG PET和F-FES PET对1-2级雌激素受体阳性乳腺癌分期的诊断准确性
Radiology. 2025 Mar;314(3):e241850. doi: 10.1148/radiol.241850.
2
ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer.基于雌激素受体的正电子发射断层扫描在雌激素受体阳性乳腺癌初始分期和疑似复发中的应用。
JAMA Netw Open. 2024 Jul 1;7(7):e2423435. doi: 10.1001/jamanetworkopen.2024.23435.
3
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南：乳腺癌》第 3.2024 版。
J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.
4
Head-to-head comparison of F-FDG and F-FES PET/CT for initial staging of ER-positive breast cancer patients.F-FDG与F-FES PET/CT用于雌激素受体阳性乳腺癌患者初始分期的头对头比较。
Eur J Hybrid Imaging. 2023 Dec 18;7(1):23. doi: 10.1186/s41824-023-00176-3.
5
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-F-Fluoro-17β-Fluoroestradiol.摘要：16α-F-氟-17β-氟雌二醇雌激素受体靶向 PET 成像的适用标准。
J Nucl Med. 2023 Mar;64(3):351-354. doi: 10.2967/jnumed.123.265420.
6
Clinical Validity of 16α-[F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.16α-[F]氟-17β-雌二醇正电子发射断层扫描/计算机断层扫描评估新诊断转移性乳腺癌雌激素受体状态的临床有效性。
J Clin Oncol. 2022 Nov 1;40(31):3642-3652. doi: 10.1200/JCO.22.00400. Epub 2022 May 18.
7
Imaging of Bone Metastases in Breast Cancer.乳腺癌骨转移的影像学表现。
Semin Nucl Med. 2022 Sep;52(5):531-541. doi: 10.1053/j.semnuclmed.2022.01.005. Epub 2022 Feb 27.
8
Diagnostic Performance of [F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast Cancer.[F]FDG PET在1-2级雌激素受体阳性乳腺癌分期中的诊断性能
Diagnostics (Basel). 2021 Oct 21;11(11):1954. doi: 10.3390/diagnostics11111954.
9
Diagnostic accuracy and safety of 16α-[F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.16α-[F]氟-17β-雌二醇 PET-CT 评估乳腺癌复发或转移病灶中雌激素受体状态的诊断准确性和安全性：一项前瞻性队列研究。
Lancet Oncol. 2019 Apr;20(4):546-555. doi: 10.1016/S1470-2045(18)30936-7. Epub 2019 Mar 4.
10
Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.18F-FDG PET/CT用于新诊断的浸润性小叶癌与浸润性导管癌全身分期的比较
J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.
Zotero 插件